https://staging.adityak.online/sjia_publication/tocilizumab-in-sjia-randomized-trial-il-6/2026-01-24T17:58:07+00:00https://staging.adityak.online/sjia_publication/canakinumab-for-sjia-phase-3-efficacy-and-safety/2026-01-24T17:59:19+00:00https://staging.adityak.online/sjia_publication/early-anakinra-leads-to-inactive-disease-in-new-onset-sjia/2026-01-24T17:59:49+00:00https://staging.adityak.online/sjia_publication/consensus-definitions-management-of-macrophage-activation-syndrome/2026-01-24T18:00:37+00:00https://staging.adityak.online/sjia_publication/sjia-associated-lung-disease-emerging-insights/2026-01-24T18:01:08+00:00https://staging.adityak.online/sjia_publication/jak-inhibition-for-refractory-sjia-real-world-cohort/2026-01-24T18:02:30+00:00https://staging.adityak.online/sjia_publication/updated-management-guidance-for-sjia/2026-01-24T18:02:50+00:00https://staging.adityak.online/sjia_publication/il-18-as-a-biomarker-in-sjia-and-mas/2026-01-24T18:03:10+00:00https://staging.adityak.online/sjia_publication/ferritin-dynamics-for-early-mas-detection/2026-01-24T18:03:29+00:00https://staging.adityak.online/sjia_publication/canakinumab-long-term-follow-up-in-sjia/2026-01-24T18:03:47+00:00